Trevi Therapeutics Set to Showcase at Key Investor Conferences

Trevi Therapeutics Engages with Investors and Medical Community

Trevi Therapeutics, Inc. (NASDAQ: TRVI) has announced exciting developments for the upcoming months as they prepare for participation in several high-profile conferences that will showcase their innovative therapies. As a clinical-stage biopharmaceutical company, Trevi is dedicated to providing effective solutions for chronic cough related to idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Upcoming Conferences Highlighting Trevi's Innovations

In the coming weeks, Trevi's senior management, led by executives like Chief Commercial Officer Farrell Simon, will attend notable conferences that provide a platform to engage with investors and medical professionals. These events are critical for Trevi as they aim to present their investigational therapy, Haduvio™ (oral nalbuphine ER), which is designed to treat chronic cough effectively.

3rd Chief Commercial Officer Summit

Set for October 23-24, the 3rd Chief Commercial Officer Summit in Philadelphia is anticipated to be a pivotal event. Trevi will present an oral discussion focused on the role of commercial strategies in clinical trial recruitment. This key presentation is scheduled for October 23 at 1:30 PM EDT. This summit offers a unique opportunity for industry leaders to exchange insights and foster growth within the biopharmaceutical sector.

BIO-Europe Conference

Following the commercial summit, Trevi will also attend the BIO-Europe conference from November 4 to 6 in Stockholm. This prominent conference attracts a diverse group of pharmaceutical experts and offers excellent networking opportunities. Farrell Simon will represent Trevi, allowing the company to highlight its vision and the promising prospects of Haduvio.

Stifel 2024 Healthcare Conference Insights

Trevi's commitment to innovation continues as they prepare for the Stifel 2024 Healthcare Conference on November 18-19 in New York. During this notable event, executives Jennifer Good, Trevi's President and CEO, and Lisa Delfini, Chief Financial Officer, will deliver a corporate presentation on November 18 at 11:30 AM EDT. This platform will be instrumental in clarifying Trevi's objectives and the profile of Haduvio.

The Importance of Haduvio

Haduvio is notably positioned as an extended-release dual ????-opioid receptor agonist and ????-opioid receptor antagonist. Its unique mechanism aims to address the painful burden of chronic cough, significantly impacting quality of life for patients battling IPF and RCC. The potential of Haduvio to improve treatment outcomes is crucial, particularly in a landscape devoid of approved therapies for these serious conditions.

The Need for Effective Therapies

Chronic cough can drastically alter one's quality of life, leading to a decline in social interactions, physical health, and mental well-being. In IPF, persistent coughing can potentially intensify the progression of the disease, increasing mortality risk or leading to lung transplants. Current therapies offer limited relief, emphasizing the urgent need for innovations like Haduvio.

Expanding Reach for Chronic Cough Sufferers

Trevi's focus on RCC indicates a significant market opportunity, with Haduvio's potential application extending to patients suffering from moderate to severe symptoms. This expansion is especially important as it highlights Trevi's commitment to addressing unmet medical needs, particularly as there are no FDA-approved treatments for RCC in the United States.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is dedicated to the development of groundbreaking therapies such as Haduvio™. With a clear vision, the company aims to bring forth long-awaited solutions for chronic cough treatment, driven by a robust scientific foundation and a commitment to patient-centric development.

Additionally, it's essential to note that the safety and efficacy of Haduvio have not been evaluated by any regulatory authority. Hence, as Trevi progresses, they are focused on rigorous development pathways to secure approval for this vital therapy.

Frequently Asked Questions

1. What is Haduvio and its purpose?

Haduvio is an investigational therapy aimed at treating chronic cough associated with IPF and RCC, designed to offer significant clinical benefits.

2. When are the upcoming conferences Trevi Therapeutics will attend?

Trevi will participate in the Chief Commercial Officer Summit on October 23-24, BIO-Europe on November 4-6, and the Stifel 2024 Healthcare Conference on November 18-19.

3. Who will represent Trevi Therapeutics at these conferences?

Executives including Farrell Simon, Jennifer Good, and Lisa Delfini will represent Trevi at various conferences.

4. Why is chronic cough a significant issue?

Chronic cough can severely affect patients' quality of life and is often linked to serious conditions like IPF, making effective treatment essential.

5. What are the implications of Haduvio's development?

The development of Haduvio offers hope for a breakthrough treatment for chronic cough, addressing a significant unmet medical need in the industry.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.